FDA Clearance Tracker · P230042
Optune Lua
Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Oct 15, 2024
Approved
Time to decision
305 days
Received Dec 15, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P230042
- Device name
- Optune Lua
- Applicant
- Novocure, GmbH
- Applicant location
- Baar
- Received
- Dec 15, 2023
- Decided
- Oct 15, 2024
- Decision
- Approved
- Supplements
- 7 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel is indicated for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code SDA (Electrical tumor treatment fields for non-small cell lung cancer).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Novocure, GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Optune PaxBreakthroughPMA
P250034 · Decided Feb 11, 2026 · 180 days after receipt
Device type: Low Electric Field Generator for Pancreatic Cancer Treatment (SHC) · General & Plastic Surgery
- OPTUNE (FORMERLY THE NOVOTTF-100A SYSTEM)PMA supplement
P100034-S013 · Decided Oct 5, 2015 · 178 days after receipt · Panel Track
Device type: Stimulator, low electric field, tumor treatment (NZK) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.